+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SAMRATPH SAMRATPH

Samrat Pharmachem Share Price

₹243.20 +10.1 (4.33%)
28.00% Gain from 52W Low

14 Oct, 2026 4:01 PM (IST)

Samrat Pharmachem live price: ₹243.20. It opened at ₹231 vs previous close ₹233; intraday high/low: ₹245/₹231. The 50 & 200 DMA stand at ₹235.00/₹241.30.

Samrat Pharmachem Performance

  • Today's Low
  • ₹231
  • Today's High
  • ₹245
  • 52 Week Low
  • ₹190
  • 52 Week High
  • ₹310
  • Open Price₹231
  • Previous Close₹233
  • Volume1,636
  • 50 DMA₹235.00
  • 100 DMA₹233.70
  • 200 DMA₹241.30

Samrat Pharmachem Chart

Investment Returns

  • Over 1 Month + 7.07%
  • Over 3 Month -4.25%
  • Over 6 Month + 14.91%
  • Over 1 Year -18.18%

Smart Investing Starts Here Start SIP with Samrat Pharmachem for Steady Growth!

Invest Now

Samrat Pharmachem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -34
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 75
  • P/B Ratio
  • 1.1
  • Average True Range
  • 11.8
  • EPS
  • -7.1
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.1
  • RSI
  • 51.88
  • MFI
  • 61.27

Latest Stock News Updates

Samrat Pharmachem Ltd-$ - 530125 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74(5) of SEBI (DP) Regulations for the quarter ended 30th September 2026.

Samrat Pharmachem Ltd-$ - 530125 - Board Meeting Intimation for Board Meeting Intimation For Un-Audited Financial Results For The Quarter Ended September 30, 2026

Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Samrat Pharmachem Limited - has informed BSE Ltd that the meeting of Board of Directors of the Company is scheduled on 14/11/2026, to consider and approve the Un-audited financial results for the quarter ended September 30, 2026.

Samrat Pharmachem Ltd-$ - 530125 - Closure of Trading Window

Trading window shall remain closed from 01-10-2026 till 48 hours after declaration of UFR for the quarter ended September 30, 2026.

Samrat Pharmachem Financials

Samrat Pharmachem Technicals

EMA & SMA

Current Price
₹243.20
+ 10.1 (4.33%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹235.20
  • 50 Day
  • ₹235.00
  • 100 Day
  • ₹233.70
  • 200 Day
  • ₹241.30

Resistance and Support

239.6 Pivot Speed
  • R3 259.10
  • R2 252.00
  • R1 244.70
  • S1 230.40
  • S2 223.30
  • S3 216.00

Samrat Pharmachem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-14 Quarterly Results
2026-08-14 Quarterly Results
2026-05-30 Audited Results
2026-02-13 Quarterly Results
2025-11-14 Quarterly Results
Date Purpose Remarks
2025-09-18 FINAL Rs.1.00 per share(10%)Final Dividend
2024-09-19 FINAL Rs.1.00 per share(10%)Final Dividend
2023-09-18 FINAL Rs.1.00 per share(10%)Dividend
View Samrat Pharmachem Dividend History Arrow

Samrat Pharmachem Shareholding Pattern

49.09%
47.67%
3.24%
0%

About Samrat Pharmachem

Samrat Pharmachem is engaged in the business of business of pharmaceutical chemicals. The company gets its income from selling of pharmaceutical chemicals in domestic and international market. View More
  • NSE Symbol
  • SAMRATPH
  • BSE Symbol
  • 530125
  • ISIN
  • INE103E01016

Similar Stocks to Samrat Pharmachem

Samrat Pharmachem FAQs

Samrat Pharmachem share price is ₹243 As on 14 October, 2026 | 19:37

The Market Cap of Samrat Pharmachem is ₹75.1 Cr As on 14 October, 2026 | 19:37

The P/E ratio of Samrat Pharmachem is -34 As on 14 October, 2026 | 19:37

The PB ratio of Samrat Pharmachem is 1.1 As on 14 October, 2026 | 19:37

The 52 week High & Low of Samrat Pharmachem is ₹310/₹190 respectively As on 14 October, 2026 | 19:37

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23